Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?

OBJECTIVES: Vascular endothelial growth factor (VEGF) is involved in physiological angiogenesis, but also is considered one of the key factors that promotes tumor angiogenesis. CIGB-247 is a VEGF-based vaccine that has been evaluated in phase I clinical trial patients with advanced solid tumors. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez Ramírez, Javier, Bequet-Romero, Mónica, Morera Díaz, Yanelys, Hernández-Bernal, Francisco, Ayala Avila, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558718/
https://www.ncbi.nlm.nih.gov/pubmed/31182141
http://dx.doi.org/10.1186/s13104-019-4368-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558718/
https://www.ncbi.nlm.nih.gov/pubmed/31182141
http://dx.doi.org/10.1186/s13104-019-4368-z

Ejemplares similares